Gene Modification
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
CRISPR Gene Editing Therapy Can Be Administered Twice, Intellia Study Suggests
CRISPR, gene editing, Intellia Therapeutics, transthyretin amyloidosis, gene therapy, re-dosing
Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership
Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval
Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy
Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials
Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy
Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data
Preliminary CRISPR-Based HIV Treatment Study Shows Limited Success
CRISPR, HIV, gene editing, treatment, study, curative potential, early study, limited success
Revival of Gene Editing Clinical Trials in China Post CRISPR Baby Scandal
CRISPR baby scandal, China, gene editing, clinical trials, restart, regulations, ethics, CRISPR-Cas9, genetic diseases, biotechnology.
Moderna Terminates Gene Editing Partnership, Shifts Focus to mRNA Technology
Moderna, Metagenomi, gene editing, partnership, mRNA technology, biotechnology, biobucks, deal termination
Prime Medicine Secures FDA Approval for Pioneering Gene Editing Therapy Trial
Prime Medicine, FDA approval, gene editing, clinical trial, innovative therapy, genetic diseases